Navigation Links
Genopole(R) is Organizing an Advanced Course on Stem Cells and Their Therapeutic Applications

From November 18th to 22nd, 2007, under the responsibility of Marc Peschanski, director of I-Stem(1), Genopole(R) is organizing an advanced course on stem cells and their therapeutic applications, aimed at exploring the latest advancements of research in this field, with input from 17 renowned specialists worldwide. Major topics to be covered include embryonic stem cells, mesenchymatic, hematopoetic, and organ stem cells and cloning.

Stem cells, whether embryonic or tissue-specific, are seen today as extremely useful tools showing therapeutic promising approach for many diseases.

Reproduced and differentiated on demand, they can enable the transfers of biological products needed for gene and cell therapy or represent flexible and powerful tools for screening molecules for predictive toxicology or therapeutic efficacy trials.

The body of gathered knowledge, which is already very large, can be even further extended, for example, to the hematopoetic system or epidermis. A certain number of key mechanisms remain unknown, particularly the two main characteristics of stem cells: on the one hand, their ability for self-renewal and, on the other, for differentiation.

This area of research has become a top priority at Genopole; next September 11th, Genopole, in cooperation with the AFM, Inserm and Universite d'Evry-Val-d'Essonne, will be inaugurating the I-Stem laboratory, directed by Marc Peschanski, one of the first researchers authorized to work on stem cells in France.

The audience will be limited to 40 participants. This course is intended for biologists already involved in stem cell research and wishing to reach a more detailed understanding of this area.


'"/>




Page: 1

Related medicine news :

1. Advanced STD programs required
2. Hope For Patients With Advanced Breast Cancer
3. HIV Vaccine Field Trials In Advanced Stage
4. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
5. Eddie Thompson Receives Advanced Cancer Treatment
6. PSA Can Predicts The Treatment Response In Advanced Prostate Cancer
7. Rapid Aging of Arteries In People With Advanced Heart Disease
8. Aricept Cleared for Advanced Alzheimers Treatment
9. Adding Radiation Therapy For Treatment of Advanced Prostate Cancer May Offer Benefit
10. New Pill for Patients With Advanced Prostate Cancer
11. Hormone Drug Type Makes Survival Difference in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of ... many times purer and more potent than the market has seen before. Swissx uses ... as well as a patented chromatography process for extraction, to produce its CBD oil--maximizing ...
(Date:4/26/2017)... ... April 26, 2017 , ... Intalere, the healthcare ... podcast, “Make Plans for MACRA,” highlighting the impact of the Medicare ... and how physicians and other clinicians are reimbursed for the care they deliver ...
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... Miami, FL (PRWEB) , ... April 26, 2017 , ... ... twenty-fifth anniversary as a dentist. , “I could have never imagined back in 1991 ... and personally,” said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
(Date:4/18/2017)... 2017 Viverae ® , a leader in ... of IBM ® Watson Campaign Automation, implementing behavioral ... for a personalized experience. Through digital engagement, the platform ... in real time. The enhanced experience drives engagement by ... wherever they are in their journey to health. ...
Breaking Medicine Technology: